Dashboard
Manage Tickers

CRMD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

d-boral-capital-maintains-buy-on-cormedix-maintains-14-price-target
D. Boral Capital Maintains Buy on Cormedix...
11/12/2025 19:09:45

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:CRMD) with a Buy and maintains $14 price target.

needham-maintains-buy-on-cormedix-lowers-price-target-to-16
Needham Maintains Buy on Cormedix, Lowers ...
11/12/2025 19:00:08

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $20 to $16.

cormedix-q3-profit-soars-as-defencath-dialysis-demand-exceeds-expectations
CorMedix Q3 Profit Soars As DefenCath Dial...
11/12/2025 16:49:31

CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melin...

pharming-group-posts-upbeat-q3-results-joins-on-holding-bigbearai-holdings-and-other-big-stocks-moving-higher-on-wednesday
Pharming Group Posts Upbeat Q3 Results, Jo...
11/12/2025 16:19:01

update-cormedix-q3-adj-eps-057-misses-065-estimate-adj-eps-excludes-one-time-tax-benefit-597m
UPDATE: Cormedix Q3 Adj. EPS $0.57 Misses ...
11/12/2025 13:55:13

cormedix-sees-fy2025-sales-390000m-410000m-vs-283692m-est
Cormedix Sees FY2025 Sales $390.000M-$410....
11/12/2025 12:40:32

CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter ...

cormedix-sees-q4-sales-115000m-135000m-vs-118847m-est
Cormedix Sees Q4 Sales $115.000M-$135.000M...
11/12/2025 12:40:18

Cormedix (NASDAQ:CRMD) sees Q4 sales of $115.000 million-$135.000 million vs $118.847 million analyst estimate.

cormedix-q3-eps-126-beats-063-estimate-sales-104270m-beat-86023m-estimate
Cormedix Q3 EPS $1.26 Beats $0.63 Estimate...
11/12/2025 12:32:10

Cormedix (NASDAQ:CRMD) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $0.63 by 100...

earnings-scheduled-for-november-12-2025
Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

top-stocks-with-earnings-this-week-plug-oklo-circle-and-more
Top Stocks With Earnings This Week: Plug, ...
11/10/2025 13:38:37

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, P...

cormedix-says-defencath-receives-innovative-technology-designation-from-vizient
CorMedix Says DefenCath Receives Innovativ...
10/23/2025 12:32:58

CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for lif...

beyond-the-numbers-4-analysts-discuss-cormedix-stock
Beyond The Numbers: 4 Analysts Discuss Cor...
10/21/2025 22:01:38

rbc-capital-maintains-outperform-on-cormedix-raises-price-target-to-22
RBC Capital Maintains Outperform on Cormed...
10/21/2025 14:34:57

RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $21 ...

d-boral-capital-upgrades-cormedix-to-buy-announces-14-price-target
D. Boral Capital Upgrades Cormedix to Buy,...
10/20/2025 13:33:06

D. Boral Capital analyst Jason Kolbert upgrades Cormedix (NASDAQ:CRMD) from Hold to Buy and announces $14 price target.

Core News & Articles
Market-Moving News for October 20th
10/20/2025 11:36:19

REPL: 81% | The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivol...

cormedix-sees-q3-unaudited-pro-forma-net-revenue-over-125m-raises-fy-2025-pro-forma-net-revenue-guidance-to-375m
CorMedix Sees Q3 Unaudited Pro Forma Net R...
10/20/2025 11:32:37

cormedix-files-for-offering-of-up-to-63m-shares-of-common-stock-by-selling-securityholders
CorMedix Files For Offering Of Up To 6.3M ...
09/30/2025 21:22:55

https://www.sec.gov/Archives/edgar/data/1410098/000121390025094067/ea0258874-s3_cormedix.htm

cormedix-completes-enrollment-in-phase-iii-respect-trial-for-rezzayo-in-fungal-infection-prevention
CorMedix Completes Enrollment In Phase III...
09/29/2025 13:20:34

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allo...

analyst-expectations-for-cormedixs-future
Analyst Expectations For Cormedix's Future
09/09/2025 18:01:00

jmp-securities-reiterates-market-outperform-on-cormedix-maintains-22-price-target
JMP Securities Reiterates Market Outperfor...
09/09/2025 12:37:52

JMP Securities analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $22 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION